Last updated on March 2020

Non-interventional Study of Cabozantinib in Adults With Advanced Renal Cell Carcinoma

Brief description of study

The objective of this study is to understand the utilization of cabozantinib in subjects with advanced renal cell carcinoma (RCC) following prior VEGF-targeted therapy in real life settings in terms of dose modifications due to adverse events (AEs) when used as a second line therapy or third and later line therapy. Other patterns of use of cabozantinib will also be described.

Detailed Study Description

The study will follow the real-life management of patients in clinical practice. Visits will take place according to the study site's clinical practice. Cabozantinib is to be administered as directed by the investigator according to the study site's usual clinical practice and the Cabometyx Summary of Product Characteristics (SmPC).

Clinical Study Identifier: NCT03419572

Find a site near you

Start Over

Grenoble University Hospital

Grenoble, France
  Connect »